EMERGENT BIOSOLUTIONS INC. Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent
EMERGENT BIOSOLUTIONS INC. (EBS) reported Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent of $0 for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1 · last filed 2024-11-07
- EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), tax, portion attributable to parent for the quarter ending 2024-09-30 was $0.00.
- EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), tax, portion attributable to parent for the quarter ending 2024-06-30 was $0.00.
- EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), tax, portion attributable to parent for the quarter ending 2024-03-31 was $0.00.
- EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), tax, portion attributable to parent for the quarter ending 2023-12-31 was $1.30M.
- EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), tax, portion attributable to parent for fiscal 2023 was -$2.20M, a 146.81% decline from fiscal 2022.
- EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), tax, portion attributable to parent for fiscal 2022 was $4.70M, a 67.86% increase from fiscal 2021.
- EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), tax, portion attributable to parent for fiscal 2021 was $2.80M.
- EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), tax, portion attributable to parent for fiscal 2020 was -$4.40M.
| Period end | Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2024-09-30 | $0.00 10-Q · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | $1.30M derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-07 | $0.00 10-Q · filed 2024-08-07 | $1.30M derived: sum of 3 quarters · filed 2024-08-07 | $100.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-02 | $1.30M derived: sum of 2 quarters · filed 2024-05-02 | $100.00K derived: sum of 3 quarters · filed 2024-11-07 | -$1.70M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $100.00K derived: sum of 2 quarters · filed 2024-11-07 | -$1.70M derived: sum of 3 quarters · filed 2024-11-07 | -$2.20M 10-K · filed 2024-03-08 |
| 2023-09-30 | -$1.20M 10-Q · filed 2024-11-07 | -$3.00M derived: sum of 2 quarters · filed 2024-11-07 | -$3.50M 10-Q · filed 2024-11-07 | -$5.50M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$1.80M 10-Q · filed 2024-08-07 | -$2.40M 10-Q · filed 2024-08-07 | -$4.30M derived: sum of 3 quarters · filed 2024-08-07 | -$2.10M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | -$600.00K 10-Q · filed 2024-05-02 | -$2.50M derived: sum of 2 quarters · filed 2024-05-02 | -$300.00K derived: sum of 3 quarters · filed 2024-05-02 | $1.60M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | -$1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $300.00K derived: sum of 2 quarters · filed 2024-03-08 | $2.20M derived: sum of 3 quarters · filed 2024-03-08 | $4.70M 10-K · filed 2024-03-08 |
| 2022-09-30 | $2.20M 10-Q · filed 2023-12-11 | $4.10M derived: sum of 2 quarters · filed 2023-12-11 | $6.60M 10-Q · filed 2023-12-11 | $8.10M derived: sum of 4 quarters · filed 2024-03-08 |
| 2022-06-30 | $1.90M 10-Q · filed 2023-08-09 | $4.40M 10-Q · filed 2023-08-09 | $5.90M derived: sum of 3 quarters · filed 2024-03-08 | $8.20M derived: sum of 4 quarters · filed 2024-03-08 |
| 2022-03-31 | $2.50M 10-Q · filed 2023-05-10 | $4.00M derived: sum of 2 quarters · filed 2024-03-08 | $6.30M derived: sum of 3 quarters · filed 2024-03-08 | $6.00M derived: sum of 4 quarters · filed 2024-03-08 |
| 2021-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $3.80M derived: sum of 2 quarters · filed 2024-03-08 | $3.50M derived: sum of 3 quarters · filed 2024-03-08 | $2.80M 10-K · filed 2024-03-08 |
| 2021-09-30 | $2.30M 10-Q · filed 2022-11-09 | $2.00M derived: sum of 2 quarters · filed 2022-11-09 | $1.30M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | -$300.00K 10-Q · filed 2022-08-02 | -$1.00M 10-Q · filed 2022-08-02 | ||
| 2021-03-31 | -$700.00K 10-Q · filed 2022-04-29 | |||
| 2020-12-31 | -$4.40M 10-K/A · filed 2023-12-11 | |||
| 2019-12-31 | -$900.00K 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |